Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study

Area of Science:

• Pediatric Oncology
• Sarcoma Research
• Clinical Trials

Background:

• Ewing sarcoma (EWS) is a rare bone and soft tissue cancer primarily affecting children and young adults.
• The Euro-EWING99 study represents one of the largest international collaborations to date investigating EWS treatment protocols.
• Understanding prognostic factors is crucial for tailoring treatment and improving patient outcomes in EWS.

Purpose of the Study:

• To characterize the cohort of patients enrolled in the Euro-EWING99 study.
• To report survival outcomes, including overall survival (OS) and progression-free survival (PFS).
• To identify prognostic factors influencing OS and PFS in Ewing sarcoma patients.

Main Methods:

• Prospective recruitment of 3,395 EWS patients aged under 50 between 1999 and 2015.
• Standardized induction chemotherapy (VIDE regimen) followed by local therapy (surgery/radiotherapy) and risk-adapted consolidation.
• Assessment of survival endpoints (OS, PFS, local control) and prognostic factor analysis.

Main Results:

• The cohort comprised patients with localized disease, pleuropulmonary, and extrapulmonary metastases.
• Five-year PFS and OS rates for the entire cohort were 55.4% and 64.6%, respectively.
• Independent prognostic factors for PFS and OS included metastatic status, patient age, tumor volume, and histologic response.

Conclusions:

• The Euro-EWING99 study provides a comprehensive dataset and landmark findings for Ewing sarcoma.
• Complete histologic response after neoadjuvant therapy is a significant predictor of improved survival.
• These findings reinforce the importance of assessing treatment response in EWS management.